JP2766811B2 - Aqueous skin external preparation - Google Patents
Aqueous skin external preparationInfo
- Publication number
- JP2766811B2 JP2766811B2 JP28235294A JP28235294A JP2766811B2 JP 2766811 B2 JP2766811 B2 JP 2766811B2 JP 28235294 A JP28235294 A JP 28235294A JP 28235294 A JP28235294 A JP 28235294A JP 2766811 B2 JP2766811 B2 JP 2766811B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- external preparation
- weight
- aqueous
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 11
- 229930091371 Fructose Natural products 0.000 claims description 11
- 239000005715 Fructose Substances 0.000 claims description 11
- 229920002307 Dextran Polymers 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 239000008346 aqueous phase Substances 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 210000004927 skin cell Anatomy 0.000 description 11
- 230000003204 osmotic effect Effects 0.000 description 9
- 239000003792 electrolyte Substances 0.000 description 8
- 210000003722 extracellular fluid Anatomy 0.000 description 6
- 208000017520 skin disease Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 231100000245 skin permeability Toxicity 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【０００１】[0001]
【産業上の利用分野】本発明は、皮膚細胞に対して電解
質バランス、浸透圧バランスを調整し、活性化する水性
皮膚外用剤に関する。更に、詳細には、皮膚細胞の細胞
機能低下による諸疾患の改善の効果が著しく改良された
安全性の高い水性皮膚用外用剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an aqueous external skin preparation which regulates and activates an electrolyte balance and an osmotic pressure balance for skin cells. More specifically, the present invention relates to a highly safe external preparation for aqueous dermatology in which the effect of ameliorating various diseases due to decreased cell function of skin cells is significantly improved.
【０００２】[0002]
【従来の技術】近年、外用剤に関する技術は、進歩が著
しく、数多くの外用剤が開発されており、外用剤として
も期待されている効果は、ａ．皮膚の殺菌、消毒作用、
ｂ．皮膜作用、ｃ．皮膚の水分の蒸発を防ぎ、保湿の促
進作用の３つである。2. Description of the Related Art In recent years, the technology relating to external preparations has made remarkable progress, and many external preparations have been developed. The effects expected as external preparations are as follows: a. Disinfection, disinfection of skin,
b. Film action, c. The three functions are to prevent evaporation of water from the skin and to promote moisturizing.
【０００３】然し乍ら、従来の外用剤では、皮膚殺菌作
用及び皮膚の保護の目的は達せられても、皮膚の毛細血
管の循環及び機能低下による皮膚疾患の皮膚細胞分裂機
能低下による諸疾患を改善することは、困難であった。
例えば、塩化ナトリウムを添加した外用剤では皮膚を刺
激したり、殺菌をすることはできても、皮膚の水分の蒸
発を防止しての保湿の促進作用を改善することは、難し
かった。[0003] However, the conventional topical preparations achieve the purpose of skin bactericidal action and protection of the skin, but ameliorate various diseases caused by a decrease in skin cell division function, which is a skin disorder due to a decrease in circulation and function of capillaries in the skin. That was difficult.
For example, although an external preparation containing sodium chloride can irritate and sterilize the skin, it has been difficult to improve the action of promoting moisture retention by preventing the evaporation of skin moisture.
【０００４】従来、外用剤の成分として、塩化ナトリウ
ムを含む肌を和らげるクリ−ムは、米国特許第3、574、
854号に記載され、また、グルコ−スを混合した肌を滑
らかにする糖の成分に関するものは、米国特許第3、85
9、436号に記載され、シェ−ビング用デキストラン水溶
液は、米国特許第３、777、587号に記載されている。そ
して、果糖は、栄養源となり、全身の細胞機能を促進
し、生体の代謝機能を増し、解毒採用もある。然し乍
ら、果糖は、経口的栄養補給薬及び静脈注射又は筋肉注
射により体内に補給されるものであって、皮膚へ直接塗
布する外用剤へは、果糖を添加しても、果糖による効果
はあまり期待できない。また、デキストランは皮膚透過
性の性質から、化粧品基材に配合されるが、性状を保持
し、その腐敗防止のためには、配合量に制限があり、不
都合であった。Conventionally, a soothing cream containing sodium chloride as a component of an external preparation has been disclosed in US Pat. No. 3,574,
No. 854, described in U.S. Pat.
No. 9,436, and aqueous dextran solutions for shaving are described in U.S. Pat. No. 3,777,587. And fructose becomes a nutrient source, promotes the cell function of the whole body, increases the metabolic function of the living body, and also employs detoxification. However, fructose is replenished into the body by oral nutritional supplements and intravenous or intramuscular injection. Even if fructose is added to external preparations that are directly applied to the skin, the effects of fructose are expected to be low. Can not. In addition, dextran is incorporated into a cosmetic base material due to its skin permeability, but the amount of dextran is limited in order to maintain its properties and prevent its decay, which is inconvenient.
【０００５】[0005]
【発明が解決しようとする課題】本発明は、これらの問
題点を解決し、皮膚細胞間質液と同様な環境を皮膚表面
に与え、電解質バランス、浸透圧バランスの保持を本来
的に有することにより、皮膚の表層からも障害細胞の正
常化を促進するものであり、皮膚細胞に対する電解質バ
ランス、浸透圧バランスを調整して、皮膚細胞の活性促
進を図るものとし、シミ等の場合は皮下細胞を刺激、分
裂させ、治療させることができ、また、頭皮、ワキガ等
に対しては、浸透圧作用により毛母細胞を刺激し、発毛
及び脱臭作用を促進させる水性外用剤を提供することを
目的とする。SUMMARY OF THE INVENTION The present invention solves these problems and provides an environment similar to that of skin interstitial fluid to the skin surface, and inherently has an electrolyte balance and an osmotic pressure balance. It promotes the normalization of damaged cells from the surface layer of the skin, and adjusts the electrolyte balance and osmotic pressure balance for the skin cells to promote the activity of the skin cells. To provide an aqueous external preparation that stimulates hair mother cells by osmotic action to promote hair growth and deodorization for the scalp, armpits, etc. Aim.
【０００６】[0006]
【課題を解決するための手段】本発明は、上記の技術的
な課題の解決のためになされたもので、塩化ナトリウム
を全体の重量に対して０．５〜１０重量％として、果糖
を１０〜２０重量％、デキストランを５〜３０重量％と
して、水相成分に均質に溶解したことを特徴とする水性
皮膚外用剤を提供する。DISCLOSURE OF THE INVENTION The present invention has been made to solve the above technical problem, and the fructose content is 10 to 10% by weight based on the total weight of sodium chloride. An aqueous skin external preparation characterized by being homogeneously dissolved in an aqueous phase component in an amount of -20% by weight and dextran in an amount of 5-30% by weight.
【０００７】即ち、本発明の水性皮膚外用剤は、人間の
皮膚における病変である炎症、色素沈着、脱毛等の各症
状の原因は、紫外線、化学物質等の種々の因子が関連し
たものとなってい、その細胞レベルでの変化により、細
胞内呼吸の障害が生じ、細胞と間質液との間の物質の輸
送能力の低下を招き、細胞と間質液との間の物質の輸送
の低下が生じ、細胞内の栄養物質の不足を生じさせると
いった悪循環をなすものである。以上のような細胞レベ
ルでの変化を生じさせる原因は、多様なものがあり、特
に皮膚細胞においては、先天性異常を除外した多くの場
合は、毛細血管の症変や、圧迫等による血行障害による
もの、また、これ等の両者が混合したもの等が原因と考
えられている。That is, the aqueous skin external preparation of the present invention causes various symptoms such as inflammation, pigmentation, and hair loss, which are lesions in human skin, due to various factors such as ultraviolet rays and chemical substances. The change at the cellular level causes impairment of intracellular respiration, resulting in a decrease in the ability to transport substances between cells and interstitial fluid, and a decrease in transport of substances between cells and interstitial fluid. And a vicious cycle of causing a shortage of nutrients in cells. There are various causes for the above-mentioned changes at the cell level.Especially, in skin cells, in many cases excluding birth defects, blood vessels are impaired due to changes in capillaries or compression. This is considered to be caused by the above, or a mixture of the two.
【０００８】従って、このような障害原因を除去すれ
ば、細胞は正常な活動を営むことが可能になるものであ
る。特に、表皮の細胞の場合には、外界と接する物質を
有するが故に障害が生じ易く、また、それにより細胞の
活性が低下することとなり、その結果、生体自体が備え
ている自然治癒力による回復が困難になり易い状況が、
考えられるのである。[0008] Therefore, if such a cause of the disorder is eliminated, the cells can perform normal activities. In particular, in the case of cells of the epidermis, since they have substances in contact with the outside world, they are susceptible to damage, and as a result, the activity of the cells is reduced, and as a result, the natural healing power of the living body itself is restored. The situation that is likely to be difficult,
It is possible.
【０００９】本発明は、このような状況を改善するため
に皮膚細胞間質液と同様な環境を皮膚表面に作り出し、
電解質バランス、浸透圧バランスを調整することによ
り、皮膚の表層からの障害細胞の正常化を促進するもの
であり、そのため、本発明は、塩化ナトリウム、果糖、
デキストランの各成分を、水相成分に溶解したものであ
る。According to the present invention, an environment similar to the interstitial fluid of skin cells is created on the skin surface to improve such a situation.
By adjusting the electrolyte balance and the osmotic pressure balance, the normalization of damaged cells from the surface layer of the skin is promoted. Therefore, the present invention provides sodium chloride, fructose,
Each component of dextran is dissolved in an aqueous phase component.
【００１０】本発明の水性皮膚外用剤は、以上のような
見地から成されたものである。更に、本発明による塩化
ナトリウムの配合量は、皮膚に対する浸透圧バランス、
電解質バランスの有効性、即ち、皮膚細胞を活性化でき
るような全体の重量に対して、０．５〜１０重量％とす
る。即ち、塩化ナトリウムが０．５重量％未満では、皮
層を刺激したり、殺菌はできても、皮膚から吸収される
ことはなく、かえって脱水作用を受けることがあり、１
０重量％を超えると、皮膚及び粘膜の刺激が激しくな
り、安全性にも問題が生じる。[0010] The aqueous topical skin preparation of the present invention has been made in view of the above. Furthermore, the compounding amount of the sodium chloride according to the present invention is an
The effectiveness of the electrolyte balance, i.e., 0.5 to 10% by weight, based on the total weight that can activate skin cells. That is, when the content of sodium chloride is less than 0.5% by weight, the skin layer can be stimulated or sterilized, but it is not absorbed from the skin but may be dehydrated.
If the content exceeds 0% by weight, irritation of the skin and mucous membrane becomes severe, and safety is also problematic.
【００１１】次に、果糖の配合量は、無機塩と同様な理
由により、全体の重量比率で、１０〜２０重量％とす
る。果糖が、１０重量％未満では、細胞機能の亢進性の
作用が小さく、また、生体の代謝機能も増加されにく
く、２０重量％を超えると、電解質バランスを喪失させ
る可能性がある。Next, the blending amount of fructose is set to 10 to 20% by weight in the whole weight ratio for the same reason as the inorganic salt. If fructose is less than 10% by weight, the effect of enhancing cell function is small, and the metabolic function of the living body is not easily increased. If it exceeds 20% by weight, electrolyte balance may be lost.
【００１２】更に、デキストランの配合量は、全体に対
して、５〜３０重量％とする。即ち、デキストランが５
重量％未満では、皮膚浸透性に効果が小さく、３０重量
％を超えると外用剤としての安定性に不安が生じる。Further, the amount of dextran is 5 to 30% by weight based on the whole. That is, dextran is 5
If the amount is less than 30% by weight, the effect on skin permeability is small, and if it exceeds 30% by weight, the stability as an external preparation is uneasy.
【００１３】更に、本発明による水性皮膚外用剤では、
化粧品を含む通常の外用剤の製造時に使用される水に溶
ける油分、例えばプロピレングリコ−ル、ジプロピレン
グリコ−ル等は一切含有せず、純水のみで製造するノン
オイルのものである。そして、これらの塩化ナトリウ
ム、果糖、デキストランの各成分と水相成分との混合物
に際しては、各成分の溶解を完全にするために、５０〜
６０℃の温度で溶解する。[0013] Furthermore, in the aqueous skin external preparation according to the present invention,
It is a non-oil product which does not contain any water-soluble oil, such as propylene glycol and dipropylene glycol, used in the production of ordinary external preparations including cosmetics and is produced using pure water only. Then, when mixing these components of sodium chloride, fructose and dextran with the aqueous phase component, in order to completely dissolve each component, 50 to 50%
Dissolve at a temperature of 60 ° C.
【００１４】[0014]
【作用】本発明の水性皮膚外用剤においては、皮膚に刺
激を与えずに、その外用剤を表皮に塗布し、残留させる
ことにより、浸透圧を調整することにより、皮下細胞に
組織液を循環させ、皮下細胞の活性分裂の促進により、
種々の皮膚疾患を改善することができるものである。従
って、治療改善が困難であった外用皮膚疾患である色素
沈着、脱毛症に有効なものである。In the external preparation for aqueous skin of the present invention, the external preparation is applied to the epidermis without causing irritation to the skin, and is allowed to remain. By promoting the active division of subcutaneous cells,
It can improve various skin diseases. Therefore, it is effective for pigmentation and alopecia, which are external skin diseases for which treatment improvement was difficult.
【００１５】次に、本発明の水性皮膚外用剤を具体的に
実施例により説明するが、本発明はそれらによって限定
されるものではない。Next, the aqueous topical skin preparation of the present invention will be specifically described with reference to Examples, but the present invention is not limited thereto.
【００１６】[0016]
塩化ナトリウム １０重量％ 果糖 ２０重量％ デキストラン ３０重量％ 精製水 ４０重量％ Sodium chloride 10% by weight Fructose 20% by weight Dextran 30% by weight Purified water 40% by weight
【００１７】上記の組成を混合し、均質に溶解して、本
発明の外用剤を作成した。その効能を検査するために、
色素沈着症、赤ら顔の成人女子、脱毛症の成人男子、各
々、３０名に６ケ月間に及び、検査した。その結果を次
の表にまとめる。The above composition was mixed and homogeneously dissolved to prepare an external preparation of the present invention. To test its efficacy,
Adults with hyperpigmentation, blushing, and adult males with alopecia were each examined over a period of 6 months for 30 persons. The results are summarized in the following table.
【００１８】[0018]
【表１】 [Table 1]
【００１９】表１に示す成績は、各々、［効果あり］を
２点、［ややあり］を１点、［なし］を０点として、そ
の点数を合計して、有効性として示し、そして有効率
を、［合計点／６０］×１００を計算して、括弧内に示
す。The scores shown in Table 1 are shown as effectiveness, with 2 points for [Effective], 1 point for [Slightly] and 0 for [None]. The efficiency is shown in parentheses, calculated as [total points / 60] × 100.
【００２０】以上の表１に示すように、本発明の水性皮
膚外用剤は、皮膚細胞間質液と同様な環境を作り、皮膚
疾患に適応する効能が自ら選択的に作用し、過剰な使用
によっても、副作用のおそれのない、極めて安全な外用
剤となる。即ち、以上の各成分を含有することにより、
ミトコンドリアの膜の障害によって生じる細胞内呼吸阻
害や細胞の活動源のＡＴＰの生産性の低下を防止でき、
電解質バランス、浸透圧バランスを調整し、皮膚の表相
からも障害細胞の正常化を促進することが可能になる。As shown in Table 1 above, the aqueous external preparation for skin of the present invention creates an environment similar to that of the interstitial fluid of skin cells, has the effect of adapting itself to skin diseases, and selectively acts on itself. It is also an extremely safe external preparation without side effects. That is, by containing each of the above components,
Inhibition of intracellular respiration caused by damage to the mitochondrial membrane and a decrease in the productivity of ATP as a source of cell activity
By adjusting the electrolyte balance and the osmotic pressure balance, it becomes possible to promote the normalization of damaged cells even from the skin surface.
【００２１】[0021]
【発明の効果】本発明の水性皮膚外用剤は、次のごとき
技術的効果がある。即ち、第１に、上記の成分を、水相
成分に均質に溶解したことにより、皮膚細胞間質液と同
様な環境を皮膚表面に作り出すことに成功し、皮膚に対
する浸透圧が発揮され、シミ、赤ら顔を防ぐためには、
皮下細胞を刺激、分裂させて治療に導き、浸透圧の応用
により、毛母細胞を刺激し、発毛及び脱臭作用を促進さ
せる水性皮膚外用剤が得られた。第２に、電解質バラン
ス、浸透圧バランスによる皮膚細胞活性促進外用剤とし
て、その効果は、驚異的なものであり、その有効性から
見ても、今日、悩み続けている人々に期待から見ても、
意義が極めて大きい。The external preparation for aqueous skin of the present invention has the following technical effects. That is, first, by dissolving the above components homogeneously in the aqueous phase component, the environment similar to that of the skin cell interstitial fluid was successfully created on the skin surface, and the osmotic pressure on the skin was exerted. To prevent reddish faces,
The subcutaneous cells were stimulated and divided to lead to treatment, and an osmotic pressure was applied to obtain an aqueous skin external preparation that stimulates hair mother cells and promotes hair growth and deodorization. Second, as an external preparation that promotes skin cell activity by electrolyte balance and osmotic pressure balance, its effect is phenomenal, and in view of its effectiveness, it is expected from people who are still worried today. Also,
The significance is extremely large.
【００２２】第３に、更に、安全性の高い、使用が容易
な水性皮膚外用剤を提供する。Third, the present invention provides a highly safe and easy-to-use aqueous skin external preparation.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 ＦＩ Ａ６１Ｋ 7/32 Ａ６１Ｋ 7/32 7/48 7/48 31/70 ＡＧＺ 31/70 ＡＧＺ 31/715 ＡＤＡ 31/715 ＡＤＡ 33/14 ＡＤＳ 33/14 ＡＤＳ ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 7/32 A61K 7/32 7/48 7/48 31/70 AGZ 31/70 AGZ 31/715 ADA 31/715 ADA 33 / 14 ADS 33/14 ADS
Claims (1)
０．５〜１０重量％として、果糖を１０〜２０重量％、
デキストランを５〜３０重量％として、水相成分に均質
に溶解したことを特徴とする水性皮膚外用剤。1. Fructose is 10 to 20% by weight, with sodium chloride being 0.5 to 10% by weight based on the total weight,
An aqueous skin preparation for external use characterized by comprising dextran in an amount of 5 to 30% by weight and homogeneously dissolved in an aqueous phase component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP28235294A JP2766811B2 (en) | 1994-11-17 | 1994-11-17 | Aqueous skin external preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP28235294A JP2766811B2 (en) | 1994-11-17 | 1994-11-17 | Aqueous skin external preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08143416A JPH08143416A (en) | 1996-06-04 |
| JP2766811B2 true JP2766811B2 (en) | 1998-06-18 |
Family
ID=17651303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP28235294A Expired - Lifetime JP2766811B2 (en) | 1994-11-17 | 1994-11-17 | Aqueous skin external preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2766811B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440432B1 (en) * | 1999-03-18 | 2002-08-27 | Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. | Skin cosmetic compositions containing dextran or maltodextrin and a weak carboxylic acid |
| US7815900B1 (en) | 2000-07-11 | 2010-10-19 | L'ORéAL S.A. | Use of C3-C5 monosaccharides to protect keratinous fibers |
-
1994
- 1994-11-17 JP JP28235294A patent/JP2766811B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08143416A (en) | 1996-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2681527B2 (en) | Topical for promoting cell activity | |
| EP1386613B1 (en) | Topical effervescent composition | |
| JP2988491B2 (en) | How to treat aging or light damaged skin | |
| PT789584E (en) | APPLICATION OF SUPEROXIDE-DISMUTASE (SOD) IN LIPOSOMES | |
| JPH08505630A (en) | Pharmaceutical and skin cosmetic compositions containing equine colostrum | |
| KR100673044B1 (en) | Topical Compositions for Transdermal Administration | |
| US20200214943A1 (en) | Nanoparticle-containing composition for highly efficient skin brightening, whitening, moisturizing and spot fading, and preparation method thereof | |
| JPH027287B2 (en) | ||
| Akar, H Bülent Taştan, Hakan Erbil, Ercan Arca, Zafer Kurumlu, Ali Rıza Gür | Efficacy and safety assessment of 0.5% and 1% colchicine cream in the treatment of actinic keratoses | |
| US5176918A (en) | Topical medicament | |
| CN103463627A (en) | Oral care composition containing heat-resistant superoxide dismutase and growth factors | |
| ES2240987T3 (en) | THERAPEUTIC COMPOSITION FOR EXTERNAL USE CONTAINING ADRENAL CORTICOESTEROIDS FOR THE TREATMENT OF DERMATITIS. | |
| JP2766811B2 (en) | Aqueous skin external preparation | |
| CN113693966A (en) | Innovative whitening brightening freckle-removing cream and preparation method thereof | |
| CN109771326B (en) | Composition for whitening and repairing mask | |
| JPH05221823A (en) | Water skin and head skin/hair cosmetic product | |
| JPH029561B2 (en) | ||
| JPH0212443B2 (en) | ||
| JPS61260010A (en) | Hair growing agent | |
| WO1994005279A1 (en) | Dermatological treatment compositions containing dimethylsulphone and a sulfur containing amino acid | |
| ITMI941680A1 (en) | VEGETABLE EXTRACT AGAINST BURNS | |
| KR0141930B1 (en) | External preparation for cell activation | |
| KR102012019B1 (en) | Patch for prevention and treatment of stretch mark | |
| WO2006133412A1 (en) | Methods and compositions for the prevention, suppression and elimination of oral pain | |
| JPH0525017A (en) | Skin improving composition and hair nourishing composition |